Showing papers by "Mark E. Dudley published in 2007"
TL;DR: Current investigation seeks to improve the methods for generating and administering the lymphocyte cultures, and future clinical trials aim to improve durable response rates and extend the patient populations that are candidates for treatment.
124 citations
TL;DR: Cloned cdr2-specific TCR genes provide a clinically relevant means for immunologic targeting of human gynecologic cancers and appear to serve as tumor rejection antigens in the paraneoplastic neurologic disorders.
Abstract: The onconeural antigens appear to serve as tumor rejection antigens in the paraneoplastic neurologic disorders. Here, we used an unbiased peptide binding screen, followed by studies in HLA-A2.1 transgenic mice to identify naturally processed HLA-A2.1 restricted epitopes of the paraneoplastic cerebellar degeneration breast/ovarian cancer antigen cdr2. These mice were used to clone high-avidity cdr2-specific CD8+ T cells that recognize human tumor cells presenting endogenously loaded MHC class I-cdr2 peptide. T cells with this specificity were detected in the peripheral blood of two HLA-A2.1+ paraneoplastic cerebellar degeneration patients. We cloned T cell receptor (TCR) α and β genes from cdr2-specific T cells; electroporation of RNA encoding this TCR turned nonreactive donor T cells into efficient killers of human cdr2-expressing tumor cells. Cloned cdr2-specific TCR genes provide a clinically relevant means for immunologic targeting of human gynecologic cancers.
38 citations
TL;DR: In this issue of Blood, Quintarelli and colleagues demonstrate that cytotoxic T cells engineered with cytokines, a selectable marker, and a suicide gene exhibit improved growth, enhanced antitumor functions, and an increased safety profile suitable for clinical immunotherapy.
1 citations